Radium-223 Dichloride (Ra-223)
See how this compound is being investigated across Bayer’s oncology pipeline
Explore the tumor types, areas of research, and clinical trials associated with this investigational compound.
Compound Overview
Radium-223 dichloride (Ra-223) is an alpha particle–emitting radiopharmaceutical thought to mimic calcium and form complexes with bone mineral hydroxyapatite at areas of high bone turnover.1 Its cytotoxic activity targets the interaction between prostate cancer cells and the tumor microenvironment, suppressing growth of tumor cells, abnormal osteoblast activity, and abnormal bone formation.2 Radium-223 emits high-energy alpha particles of short range (<100 μm) that may induce double-stranded DNA breaks with potential limited exposure to nearby healthy tissue and bone marrow.3,4
Clinical Trial
Tumor Type(s) | Phase | Status | Description | NCT Number |
|---|---|---|---|---|
Prostate Cancer | III | Active, Not Enrolling | Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
Bayer’s Oncology Pipeline Brochure
Explore a comprehensive overview of Bayer's oncology pipeline, including investigational compounds, clinical trials, and areas of research.
The ongoing clinical trials listed on this website represent a comprehensive overview of Bayer's clinical pipeline in Oncology, including Bayer-sponsored research and collaborative research with academic centers, cooperative groups, and other global institutions.